Inovio is bringing IMMUNO-INGENUITY to life and reshaping the future of treating and preventing cancer and infectious diseases.
Potential HPV Immunotherapy Treatment:
Global Phase III
Clinical Trial - HPV301: Revealing New Treatment Possibilities
Leading the way in activation immunotherapy
Inovio's dMAb™ PD-1 Checkpoint Inhibitors Demonstrate Higher and More Prolonged Expression Compared to Native Pembrolizumab and Nivolumab Sequences In Preclinical Studies
Inovio's DNA-Encoded Monoclonal Antibody (dMAb™) Platform Leaps Forward with First-in-Human Trial
“At Inovio, the revolutionary power of our technology is superseded only by the dedication, passion, and expertise of the team we have brought together to bring our technology to life for patients in need.”
J. Joseph Kim, Ph.D.
President and CEO
Inovio's technology is IMMUNO-INGENUITY in action
Inovio's activation immunotherapy platform is generating best-in-class immune responses in the fight against cancer and infectious diseases.